更新于：2024-11-01

Recombinant human serum albumin-interferon-alpha-2a(Jilin University Zhengyuan Information Technologies Co., Ltd.)

更新于：2024-11-01

概要

研发状态

概要

基本信息

药物类型

干扰素、融合蛋白

别名

rHSA/IFNalpha2a

靶点

IFNAR

作用机制

IFNAR激动剂(干扰素α/β受体复合体激动剂)

治疗领域

感染消化系统疾病

在研适应症

乙型肝炎

非在研适应症-

原研机构

长春吉大正元信息技术股份有限公司

在研机构

长春吉大正元信息技术股份有限公司

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

关联

100 项与 Recombinant human serum albumin-interferon-alpha-2a(Jilin University Zhengyuan Information Technologies Co., Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant human serum albumin-interferon-alpha-2a(Jilin University Zhengyuan Information Technologies Co., Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant human serum albumin-interferon-alpha-2a(Jilin University Zhengyuan Information Technologies Co., Ltd.) 相关的专利（医药）

登录后查看更多信息

项与 Recombinant human serum albumin-interferon-alpha-2a(Jilin University Zhengyuan Information Technologies Co., Ltd.) 相关的文献（医药）

2009-01-01·Acta Crystallographica Section F Structural Biology and Crystallization Communications

Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon α-2A

Article

作者: Kimberly E. Cook ; William F. Dall'Acqua ; Melissa M. Damschroder ; Vaheh Oganesyan ; Herren Wu

Recombinant human interferon alpha-2A (rhIFN-alpha-2A) has been crystallized in complex with the recombinantly produced Fab fragment of a therapeutic monoclonal antibody (MEDI545; IgG1/kappa) which targets several human interferon alpha subtypes. This constitutes the first reported crystals of a human type I interferon bound to an antibody. The orthorhombic crystals belonged to either space group I222 or I2(1)2(1)2(1), with unit-cell parameters a = 134.82, b = 153.26, c = 163.49 A. The diffraction of the crystals extended to 3.0 A resolution. The asymmetric unit contained two Fab-rhIFN-alpha-2A complexes. This corresponded to a crystal volume per protein weight (V(M)) of 3.02 A(3) Da(-1) and a solvent content of 59.3%. The corresponding three-dimensional structure is expected to shed light on the mechanism of action of MEDI545 and the molecular basis of its specificity.

2003-04-01·Current Oncology Reports2区 · 医学

New and modified interferon alfas: Preclinical and clinical data

2区 · 医学

Review

作者: Ronald M. Bukowski ; Ernest C. Borden ; Phillip A. Patten ; Paul Masci ; Blaire L. Osborn

Recombinant human interferon (IFN)-alpha was the first biotherapeutic agent approved by the US Food and Drug Administration for the treatment of a human malignancy. Its efficacy has also been demonstrated for treatment of several viral diseases. The human genome codes for 12 IFN-alpha proteins, with IFN alpha-1 and IFN alpha-2 accounting for the majority of the naturally occurring IFN-as. However, only subspecies of IFN alpha-2, recombinant human IFN alpha-2a and IFN alpha-2b, are commercially available in the United States. Other species of IFN-a may demonstrate equivalent or improved efficacy and have more tolerable side effects. This article describes ongoing preclinical and clinical studies of several new and modified IFN-alphas. A current phase I trial of a human recombinant IFN alpha-1 is described. Basic pharmacokinetics and clinical studies of polyethylene glycol (PEG) IFN alpha-2b are reviewed as well. Lastly, two novel types of IFN-a, one gene shuffled and one hybridized with human albumin, are summarized.

1992-02-19·JNCI Journal of the National Cancer Institute1区 · 医学

13-cis-Retinoic Acid Plus Interferon -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

1区 · 医学

Article

作者: Patricia Paredes-Casillas ; Scott M. Lippman ; Eduardo Holderner ; Fernando Delgadillo-Madrueño ; Mario Paredes-Espinoza ; John J. Kavanagh ; Waun Ki Hong ; Irwin H. Krakoff

BACKGROUNDChemotherapeutic study of cervical squamous cell carcinoma has shown some positive results. Complete plus partial (overall) response rates of 15%-35% (complete response rate, less than 5%) were achieved with the use of a small number of cytotoxic single agents in patients with advanced disease. In addition, overall response rates of 60%-70% (complete response rates, 10%-20%) were achieved with cisplatin-based, multiagent regimens in patients with primary, locally advanced disease. However, the lack of clear evidence that existing chemotherapy can achieve a survival benefit, coupled with the worldwide annual deaths of hundreds of thousands of women from cervical cancer, indicates the urgent need for effective systemic therapy for this disease.PURPOSEIn view of the preclinical and clinical evidence that supports testing of the novel combination of 13-cis-retinoic acid (13-cRA) plus interferon-alpha (IFN-alpha) in cervical squamous cell carcinoma, we conducted a phase II study of this regimen in locally advanced disease.METHODSTwenty-six patients with untreated, locally advanced squamous cell carcinoma of the cervix were treated daily for at least 2 months with oral 13-cRA (1 mg/kg) and subcutaneous recombinant human IFN alpha-2a (6 million units). In 21 patients (81%), the disease was stage II or higher.RESULTSThirteen patients (50%) experienced major responses (tumor regression greater than or equal to 50%) in association with resolution of symptoms; one achieved complete response, and 12 experienced partial response. Seven with partial response are improving further, four are being maintained in partial response, and one responder has relapsed during therapy. The response rate is 58% (11 of 19) in patients with stage IIB or higher disease and 66% (10 of 15) in patients with bulky disease (at least one dimension greater than or equal to 10 cm). Of the 13 non-responders, nine have stable disease and four have had disease progression during therapy. Toxicity was minimal.CONCLUSIONThese preliminary results indicate that systemic 13-cRA plus IFN alpha-2a is a highly active, well-tolerated therapy for locally advanced cervical cancer.

100 项与 Recombinant human serum albumin-interferon-alpha-2a(Jilin University Zhengyuan Information Technologies Co., Ltd.) 相关的药物交易

登录后查看更多信息